United States Diabetes Care Devices Investment Opportunities, Analysis and Forecasts to 2012

Table of Contents

1. Table Of Contents

• 1.1 List of Tables
• 1.2 List of Figures

2. Introduction

• 2.1 What Is This Report About?

3. Definitions of the Markets Covered in the Report

• 3.1 Diabetes Care Devices
• 3.2 Glucose Monitoring
  • 3.2.1 Blood Glucose Meter
  • 3.2.2 Blood Glucose Strips
• 3.3 Insulin Delivery
  • 3.3.1 Insulin Jet Injector
  • 3.3.2 Insulin Pen
  • 3.3.3 Insulin Pump
  • 3.3.4 Insulin Syringes

4. Healthcare Sector Review

• 4.1 Healthcare Expenditure
• 4.2 Healthcare Infrastructure
  • 4.2.1 Healthcare Personnel Data
  • 4.2.2 Healthcare Facilities Data

5. Regulation System

• 5.1 Regulation System
• 5.2 Medical Equipment Approval Process
  • 5.2.1 Pre-market Approval Process
  • 5.2.2 Intended use and Indications for use
  • 5.2.3 Predicate Device
  • 5.2.4 Safe and Effective
    • 13.1.1 Other Category Devices
    • 13.1.2 Post-Market Approval Process
    • 18.1.1 Compliance and Enforcement
    • 18.1.2 Registration Fee
    • 18.1.3 Approval Time

19. Pricing and Reimbursement

• 19.1 Government Policies
• 23.1 Private Insurance
• 31.1 Diagnosis Related Groups (DRG)

32. Distribution Structure

• 32.1 Distribution Structure

33. United States Medical Equipment Cross Market Comparison

34. Diabetes Care Devices Cross Country Comparison

35. Diabetes Care Devices in United States

• 35.1 Diabetes Care Devices Overall Revenues by Category (2000-2012)
• 35.2 Diabetes Care Devices Overall Company Share (2006-2007)

36. Glucose Monitoring in United States

• 36.1 Glucose Monitoring Revenues by Segment (2000-2012)
• 36.2 Glucose Monitoring Volume by Segment (2000-2012)
• 36.3 Glucose Monitoring Average Price (2000-2012)
• 36.4 Glucose Monitoring Distribution Share (2006-2007)
• 36.5 Glucose Monitoring Company Share (2006-2007)

37. Insulin Delivery in United States

• 37.1 Insulin Delivery Revenues by Segment (2000-2012)
• 37.2 Insulin Delivery Volume by Segment (2000-2012)
• 37.3 Insulin Delivery Average Price (2000-2012)
• 37.4 Insulin Delivery Distribution Share (2006-2007)
• 37.5 Insulin Delivery Company Share (2006-2007)

38. F. Hoffmann-La Roche Ltd. Company Profile

• 38.1 Company Overview
• 38.2 Value Chain Analysis
  • 38.2.1 Manufacturing
    • 38.2.1.1 In House Manufacturing
    • 38.2.1.2 Outsourcing
  • 38.2.2 Product Development
    • 38.2.2.1 Regulatory Approvals
    • 38.2.2.2 Clinical Trials
    • 38.2.2.3 Research and Development
  • 38.2.3 Sales and Marketing
    • 38.2.3.1 Partnerships and Alliances

39. LifeScan, Inc. Company Profile

• 39.1 Company Overview

40. Abbott Laboratories Company Profile

• 40.1 Company Overview
• 40.2 Value Chain Analysis
  • 40.2.1 Manufacturing
    • 40.2.1.1 In House Manufacturing
  • 40.2.2 Product Development
    • 40.2.2.1 Regulatory Approvals
    • 40.2.2.2 Clinical Trials
    • 40.2.2.3 Research and Development
  • 40.2.3 Sales and Marketing
    • 40.2.3.1 Partnerships and Alliances

41. Novo Nordisk A/S Company Profile

• 41.1 Company Overview

42. Becton, Dickinson Company Profile

• 42.1 Company Overview
• 42.2 Value Chain Analysis
  • 42.2.1 Manufacturing
    • 42.2.1.1 In House Manufacturing
  • 42.2.2 Product Development
    • 42.2.2.1 Regulatory Approvals
    • 42.2.2.2 Research and Development
  • 42.2.3 Sales and Marketing
    • 42.2.3.1 Partnerships and Alliances

43. Cholestech Corporation Company Review

• 43.1 Company Overview

44. GlucoLight Corporation Company Review

• 44.1 Company Overview
• 44.2 GlucoLight Corporation Pipeline Products
  • 44.2.1 SENTRIS-100
    • 44.2.1.1 Product Overview
    • 44.2.1.2 Product Description
    • 44.2.1.3 Product Status
    • 44.2.1.4 Product Milestone

45. GlySens Incorporated Company Review

• 45.1 Company Overview
• 45.2 GlySens Incorporated Pipeline Products
  • 45.2.1 GlySens implantable glucose sensor system
    • 45.2.1.1 Product Overview
    • 45.2.1.2 Product Description
    • 45.2.1.3 Product Status

46. Animas Corporation Company Review

• 46.1 Company Overview

47. Epinex Diagnostics Incorporated Company Review

• 47.1 Company Overview

48. Freedom Meditech, Inc. Company Review

• 48.1 Company Overview

49. Eli Lilly and Company Review

• 49.1 Company Overview
• 49.2 Value Chain Analysis
  • 49.2.1 Manufacturing
    • 49.2.1.1 In House Manufacturing
    • 49.2.1.2 Outsourcing
  • 49.2.2 Product Development
    • 49.2.2.1 Regulatory Approvals
    • 49.2.2.2 Clinical Trials
    • 49.2.2.3 Research and Development
  • 49.2.3 Sales and Marketing
    • 49.2.3.1 Partnerships and Alliances
    • 49.2.3.2 Licensing Agreements
    • 49.2.3.3 E-distribution

50. DexCom, Inc. Company Review

• 50.1 Company Overview
• 50.2 DexCom, Inc. Pipeline Products
  • 50.2.1 Continuous Glucose Monitoring System
    • 50.2.1.1 Product Overview
    • 50.2.1.2 Product Description
    • 50.2.1.3 Product Status
    • 50.2.1.4 Product Milestone
  • 50.2.2 Handheld Blood Glucose Monitor
    • 50.2.2.1 Product Overview
    • 50.2.2.2 Product Description
    • 50.2.2.3 Product Status
    • 50.2.2.4 Product Milestone

51. Home Diagnostics, Inc. Company Profile

• 51.1 Company Overview
• 51.2 Home Diagnostics, Inc. Pipeline Products
  • 51.2.1 TRUEtest
    • 51.2.1.1 Product Overview
    • 51.2.1.2 Product Description
    • 51.2.1.3 Product Status
    • 51.2.1.4 Product Milestone
    • 51.2.1.5 Product Patent Details

52. Financial Deals Landscape

• 52.1 Merger
  • 52.1.1 Sontra Medical And Echo Therapeutics Completes Merger
• 52.2 Venture Financing
  • 52.2.1 Tandem Diabetes Care Secures $13.05 Million In Series B Financing
  • 52.2.2 Seattle Medical Technologies Secures $21 Million In Series B Financing
  • 52.2.3 GlucoLight Completes Third Tranche Of Series C Round Of Financing
  • 52.2.4 Luminous Medical Secures $23.5 Million In Series B Financing
  • 52.2.5 Critical Signal Technologies Raises $6 Million In Second Round Financing
  • 52.2.6 AgaMatrix Secures $23.7 Million In Series C Financing Round
• 52.3 Debt Offerings
  • 52.3.1 LifeScan Enters Into Partnership With ResMed
  • 52.3.2 Smiths Medical Enters Into Distribution Agreement With Abbott Laboratories
  • 52.3.3 DexCom Enters Into A Joint Venture With Animas
  • 52.3.4 Insulet Corporation And DexCom Form Partnership
  • 52.3.5 Bayer HealthCare Diabetes Care Signs An Agreement With Medtronic
  • 52.3.6 Roche Signs Licensing Agreement With Alnylam Pharmaceuticals

53. Recent Developments

• 53.1 Government and Public Interest
  • 53.1.1 May 05, 2008: FDA Study Finds Insulin Pumps Linked To Injuries, Deaths In Teenagers

54. Appendix

• 54.1 Global Markets Direct Research Methodology
• 54.2 Coverage
• 54.3 Secondary Research
• 54.4 Primary Research
• 54.5 Models
• 54.6 Forecasts
• 54.7 Expert Panels
• 54.8 Currency Conversion
• 54.9 Contact Us
• 54.10 Disclaimer